Monograph Details
|
|
Immune System
> Immunization
|
|
BOOSTRIX |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Tdap. |
| Generic Name |
|
Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine (aluminum hydroxide adsorbed); susp for IM inj; preservative-free. |
| Indications |
|
Diphtheria, tetanus, and pertussis booster immunization in patients 10–18 years of age. |
| Adults and Children |
|
<10yrs or >18yrs: not recommended. 10–18yrs (≥5 yrs after last childhood DTwP or DTaP vaccine): 0.5mL IM once into deltoid muscle. |
| Contraindications |
|
Encephalopathy within 7 days after previous DTaP or DTwP vaccination. Progressive neurologic disorders. Uncontrolled epilepsy. Progressive encephalopathy. |
| Precautions |
|
Fever (≥105 F within 48 hrs), persistent inconsolable crying (≥3 hrs within 48 hrs), shock (within 48 hrs), convulsions (within 3 days), or Guillain-Barre syndrome (within 6 weeks) after previous DTaP or DTwP vaccine: see literature. Stable CNS disorders. Seizure risk. Acute illness. Immunosuppressed. Bleeding disorders. Have epinephrine inj (1:1000) available. Latex allergy. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Concomitant vaccines: see literature. Immunosuppressants: may get suboptimal response. |
| Adverse Reactions |
|
Local reactions (eg, pain), fever, headache, fatigue, GI upset. |
| Extra Text |
|
Note: Register pregnant patients exposed to Boostrix by calling (888) 825-5249. Report adverse events to VAERS by calling (800) 822-7967. Refer to www.cdc.gov for ACIP guidelines on vaccinating acutely ill patients. |
| How Supplied |
Vials (single dose)—10
Prefilled syringes—5 (without needles) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
